Probiotics in the management of colonic disorders

Current Gastroenterology Reports

Volumn 9, Issue 5, 2007, Pages 434-440

  Quigley, Eamonn M M ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE; PLACEBO; PREBIOTIC AGENT; PROBIOTIC AGENT; STEROID; SYNBIOTIC AGENT;

ANTIINFLAMMATORY ACTIVITY; BLOATING; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; COLON DISEASE; COLON SURGERY; COMBINATION CHEMOTHERAPY; CONSTIPATION; CROHN DISEASE; DIARRHEA; DIVERTICULITIS; DRUG EFFICACY; DRUG MECHANISM; ENTERITIS; FLATULENCE; HUMAN; ILEITIS; IRRITABLE COLON; LACTIC ACID BACTERIUM; MONOTHERAPY; NONHUMAN; PSEUDOMEMBRANOUS COLITIS; REVIEW; ULCERATIVE COLITIS; YEAST; COLON DIVERTICULOSIS; FEMALE; HOSPITALIZATION; MALE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TREATMENT OUTCOME;

COLITIS, ULCERATIVE; COLONIC DISEASES; CONSTIPATION; CROHN DISEASE; DIARRHEA; DIVERTICULITIS, COLONIC; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; PROBIOTICS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 38849180192     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-007-0055-7     Document Type: Review

References (69)

1. Falk PG, Hooper LV, Mitrvedt T, Gordon JI: Creating and maintaining the gastrointestinal ecosystem what we know and need to know from gnotobiology. Microbiol Mol Biol Rev 1998, 62:1157-1170.
2. Shanahan F: The host-microbe interface within the gut. Best Pract Res Clin Gastroenterol 2002, 16:915-931.
3. O'Hara AM, Shanahan F: Gut microbiota. mining for therapeutic potential. Clin Gastroenterol Hepatol 2007, 5:274-294.
4. Guarner F, Malagelada JR: Gut flora in health and disease. Lancet 2003, 361:512-519.
5. Roberfroid M: Prebiotics: the concept revisited. J Nutr 2007, 137(Suppl 2):830S-837S.
6. Rachmilewitz D, Kayatura, Karmeli F, et al.: Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004, 126:520-528.
7. Shanahan F: Probiotics: a perspective on problems and pitfalls. Scand J Gastroenterol 2003, 38(Suppl):34-36.
8. NASPGHAN Nutrition Report Committee, Michail S, Sylvester F, Fuchs G, Issenman R: Clinical efficacy of probiotics: review of the evidence with focus on children. J Pediatr Gastroenterol Nutr 2006, 43:550-557.
9. Isolauri E, Salminen S, Ouwehand AC: Microbial-gut interactions in health and disease. Probiotics. Best Pract Res Clin Gastroenterol 2004, 18:299-313.
10. Allen SJ, Okoko B, Martinez E, et al.: Probiotics for treating infections diarrhoea. Cochrane Database Syst Rev 2004, (2):CDO03048.
11. Urbancsek H, Kazar T, Mezes I, et al.: Results of a doubleblind, randomized study to evaluate the efficacy and safety of Antibiophilus in patients with radiation-induced diarrhea. Eur J Gastroenterol Hepatol 2003, 13:391-396.
12. Delia P, Sansotta G, Donato V, et al.: Use of probiotics for prevention of radiation-induced diarrhea. World J Gastroenterol 2007, 13:912-915.
13. McFarland LV: Meta-analysis of probiotics for the prevention of traveler's diarrhea. Travel Med Infect Dis 2007, 5:97-105.
14. Szajewska H, Skorka A, Dylag M: Meta-analysis: Saccharomyces boulardii for treating acute diarrhoea in children. Aliment Pharmacol Ther 2007, 25:257-264.
15. D'Souza AL, Rajkumar CH, Cooke J, et al.: Probiotics in prevention of antibiotic associated diarrhea: meta-analysis. BMJ 2002, 324:1361-1366.
16. Ahuja MC, Khamar B: Antibiotic associated diarrhea: a controlled study comparing plain antibiotic with those containing protected lactobacilli. J Indian Med Assoc 2002, 100:334-335.
17. Sazawal S, Hiremath G, Dhingra U, et al.: Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo-controlled trials. Lancet Infect Dis 2006, 6:374-382.
18. de Vrese M, Marteau PR: Probiotics and prebiotics: effects on diarrhea. J Nutr 2007, 137(Suppl 2):803S-811S.
19. Chande N, McDonald JW, MacDonald JK: Interventions for treating collagenous colitis. Cochrane Database Syst Rev 2006, (4):CD003575.
20. Koebnick C, Wagner I, Leitzmann P, et al.: Probiotic beverage containing Lactobacillus casei Shirota improves gastrointestinal symptoms in patients with chronic constiaption. Can J Gastroenterol 2003, 17:655-659.
21. Amenta M, Cascio MT, Di Fiore P, Venturini I: Diet and chronic constipation. Benefits of oral supplementation with symbiotic zir fos (Bifidobacterium longum W11 + FOS Actilight). Acta Biomed 2006, 77:157-162.
22. Banaszkiewicz A, Szajewska H: Ineffectiveness of Lactobacillus GG as an adjunct to lactulose for the treatment of constipation in children: a double-blind, placebo-controlled randomized trial. J Pediatr 2005, 146:364-369.
23. Ouwehand AC, Lagstrom H, Suomalainen T, Salminen S: Effect of probiotics on constipation, fecal azoreductase activity and fecal mucin content in the elderly. Ann Nutr Metab 2002, 46:159-162.
24. Borody TJ, Warren EF, Leis SM, et al.: Bacteriotherapy using fecal flora: toying with human motions. J Clin Gastroenterol 2004, 38:475-483.
25. Quigley EM: Germs, gas and the gut, the evolving role of the enteric flora in IBS. Am J Gastroenterol 2006, 101:334-335.
26. Kim HJ, Camilleri M, McKenzie S, et al.: A randomized controlled trail of a probiotic, VSL#3 on gut transit and symptoms in diarrhoea-predominant IBS. Aliment Pharmacol Ther 2003, 17:895-904.
27. Kim HJ, Vazquez Roque MI, Camilleri M, et al.: a randomised controlled trial of probiotic combination VSL#3 and placebo in IBS with bloating: Neurogastroenterol Motil 2005, 17:687-696.
28. O'Mahony L, McCarthy J, Kelly P, et al.: Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005, 128:541-551.
29. Whorwell PJ, Altinger L, Morel J, et al.: Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006, 101:326-333.
30. Castagliuolo I, Riegler MF, Valenik L, et al.: Saccharomyces boulardii protease inhibits the effects of clostridium difficile toxins A an B in human colonic mucosa. Infect Immun 1999, 67:302-307.
31. Chen X, Kokkotou EG, Mustafa N, et al.: Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritis. J Biol Chem 2006, 281:24449-24454.
32. Wullt M, Hagslatt ML, Odenholt I: Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial. Scand J Infect Dis 2003, 35:365-367.
33. McFarland LV: Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006, 101:812-822.
34. Quigley EM, Flourie B: Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date. Neurogastroenterol Motil 2007, 19:166-172.
35. Hamilton-Miller JMT: Probiotics in the management of irritable bowel syndrome: A review of clinical trials. Microb Ecol Health Dis 2001, 13:212-216.
36. Floch MH: A hypothesis: is diverticulitis a type of inflammatory bowel disease? J Clin Gastroenterol 2006, 40(Suppl 3):S121-S125.
37. Tursi A, Brandimarte G, Giorgetti GM, Elisei W: Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study. J Clin Gastroenterol 2006, 40:312-316.
38. Sheil B, Shanahan F, O'Mahony L: Probiotic effects on inflammatory bowel disease. J Nutr 2007, 137(Suppl 2):819S-824S.
39. Ewaschuk JB, Tejpar QZ, Soo I, et al.: The role of antibiotic and probiotic therapies in current and future management of inflammatory bowel disease. Curr Gastroenterol Rep 2006, 8:486-498.
40. Sartor RB: Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004, 126:1620-1633.
41. Shanahan F: Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases I. Pathophysiological basis and prospects for probiotic therapy in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2005, 288:G417-G421.
42. McCarthy J, O'Mahony L, O'Callaghan L, et al.: Double-blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokines. Gut 2003, 52:975-980.
43. Bai AP, Ouyang Q, Xiao XR Li SF: Probiotics modulate inflammatory cytokine secretion from inflamed mucosa in active ulcerative colitis. Int J Clin Pract 2006, 60:284-288.
44. Cui HH, Chen CL, Wang JD, et al.: Effects of probiotic on intestinal mucosa of patients with ulcerative colitis. World J Gastroenterol 2004, 10:1521-1525.
45. Borruel N, Carol M, Casellas F, et al.: Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria. Gut 2002, 51:659-664.
46. Grabig A, Paclik D, Guzy C, et al.: Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathways. Infect Immun 2006, 74:4075-4082.
47. Kruis W, Schutz E, Fric P, et al.: Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pbarmacol Ther 1997, 11:853-858.
48. Rembacken BJ, Snelling AM, Hawkey PM, et al.: Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999, 354:635-639.
49. Ishikawa H, Akedo I, Umesaki Y, et al.: Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr 2003, 22:55-63.
50. Kruis W, Fric P, Pokrotnieks J, et al.: Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004, 53:1617-1623.
51. Zocco MA, dal Verme LZ, Cremonini F, et al.: Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 2006, 23:1567-1574.
52. Kato K, Mizuno S, Umesaki Y, et al.: Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther 2004, 20:1133-1141.
53. Guslandi M, Giollo P, Testoni PA: A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003, 15:697-698.
54. Tursi A, Brandimarte G, Giorgetti GM, et al.: Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit 2004, 10:PI126-PI131.
55. Bibiloni R, Fedorak RN, Tannock GW, et al.: VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005, 100:1539-1546.
56. Borody TJ, Warren EF, Leis S, et al.: Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol 2003, 37:42-47.
57. Gionchetti P, Rizzello F, Helwig U, et al.: Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003, 124:1202-1209.
58. Mimura T, Rizzello F, Helwig U, et al.: Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004, 53:108-114.
59. Gosselink MP, Schouten WR, van Lieshout LM, et al.: Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. Dis Colon Rectum 2004, 47:876-884.
60. Kuisma J, Mentula S, Jarvinen H, et al.: Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther 2003, 17:509-515.
61. Laake KO, Bjorneklett A, Aamodt G, et al.: Outcome of four weeks' intervention with probiotics on symptoms and endoscopic appearance after surgical reconstruction with a J-configurated ileal-pouch-anal-anastomosis in ulcerative colitis. Scand J Gastroenterol 2005, 40:43-51.
62. Campieri M, Rizzello F, Venturi A, et al.: Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn's disease: a randomized controlled study vs mesalamine. Gastroenterology 2000, A781:4179.
63. Guslandi M, Mezzi G, Sorghi M, Testoni PA: Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000, 45:1462-1464.
64. Gupta P, Andrew H, Kirschner BS, Guandalini S: Is lactobacillus GG helpful in children with Crohn's disease? Results of a preliminary, open-label study. J Pediatr Gastroenterol Nutr 2000, 31:453-457.
65. Karimi O, Pena AS, van Bodegraven AA: Probiotics (VSL#3) in arthralgia in patients with ulcerative colitis and Crohn's disease: a pilot study. Drugs Today (Barc) 2005, 41:453-459.
66. Prantera C, Scribano ML, Falasco G, et al.: Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 2002, 51:405-409.
67. Rolfe VE, Fortun PJ, Hawkey CJ, Bath-Hextall F: Probiotics for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2006, 18:CDO04826.
68. Marteau P, Lemann M, Seksik P, et al.: Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut 2006, 55:842-847.
69. Bousvaros A, Guandalini S, Baldassano RN, et al.: A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm Bowel Dis 2005, 11:833-839.